Journal article
A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150
Abstract
BACKGROUND: We evaluated the activity and toxic effects of bortezomib in patients with mantle cell lymphoma.
PATIENTS AND METHODS: Thirty patients, including 29 eligible patients, were enrolled; 13 had received no prior chemotherapy. The dose of bortezomib was 1.3 mg/m2 given on days 1, 4, 8 and 11 every 21 days. Response was assessed according to the International Workshop Criteria for non-Hodgkin's lymphoma and toxicity graded using the …
Authors
Belch A; Kouroukis CT; Crump M; Sehn L; Gascoyne RD; Klasa R; Powers J; Wright J; Eisenhauer EA
Journal
Annals of Oncology, Vol. 18, No. 1, pp. 116–121
Publisher
Elsevier
Publication Date
January 2007
DOI
10.1093/annonc/mdl316
ISSN
0923-7534